Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.
about
P1343
Development of Novel Immunotherapies for Multiple MyelomaMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerExpression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.Cancer-testis (CT) antigen expression in medulloblastoma.An antigenic peptide produced by reverse splicing and double asparagine deamidationInduction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.Identifying source proteins for MHC class I-presented peptides.Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancerIdentification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesProteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.Human Tumor Antigens and Cancer Immunotherapy.Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopesHeterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma.Comparison of stable human Treg and Th clones by transcriptional profiling.MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.
P2860
Q28066890-6D70B37D-A520-4A7C-A51C-9FE5B3DE4F23Q28478930-A023D4C4-BD40-4870-A5B7-437A89740DE1Q33599094-E05FAB9A-D06C-48BF-9BEB-BEB57461EBFEQ33954883-18D9F7B7-E8FE-4617-A67B-E1E236CA5140Q34111864-583479AB-55F9-40EA-9D1E-826B062A1458Q34192290-1A8B8CF2-E041-40D4-BB5B-8ED589F431EEQ34448082-548D515D-0134-4ADA-9AC9-AEC161476727Q34553385-25FB6157-2243-4CED-9E20-D453BCA4377BQ35782660-E974C5CB-8F13-49E0-B8BB-DA335AC4F31FQ36101780-2A360399-2DCE-45F8-8A09-CE3CBC3A9048Q36402611-D5E4FE3C-5067-4171-8B29-0998EA85A6E3Q36792348-029B9CAF-9414-46C7-87FB-CC354C53EB08Q37137360-1877D9A9-44D3-4BC4-ADFB-8829F1624D1CQ38269935-D9C9B389-4B63-4CF5-9B85-BD8087DD160DQ38753922-B6973605-714B-488F-AAD7-6D40E9459FFCQ39383424-CAF82A8C-F5DB-4E51-936C-D20C412C0B89Q39539865-F117112A-13DE-4325-A047-9DBE3E99332AQ39612032-1DDA4659-7905-4BA0-AA76-A88E95874975Q40439479-1C4BB952-E38D-4995-BF6B-64CAFA65B0B5Q41533232-60FBE7B4-9204-4154-9233-BE2D1D19E72FQ41703140-359C56F6-D718-48D8-8DDB-44F2C25A9AF9Q44917645-67D4C34F-428B-40FA-A69B-F16F78373936Q51815077-92BE487C-0B8E-46C4-B163-3AAC6349ABC6Q54282269-A33E100F-7B2A-4AAD-9ADA-0FA158D1E8C6
P2860
Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@ast
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@en
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@nl
type
label
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@ast
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@en
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@nl
prefLabel
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@ast
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@en
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@nl
P2093
P356
P1476
Two new tumor-specific antigen ...... lytic T lymphocytes by HLA-A2.
@en
P2093
Anne-Sophie Maernoudt
Benoît J Van den Eynde
Catherine Germeau
Nathalie Vigneron
Pierre G Coulie
Sandra Morel
Thierry Boon
P304
P356
10.1002/IJC.20038
P577
2004-05-01T00:00:00Z